BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 21631429)

  • 1. Response to HAART in treatment-naive HIV-infected patients with a prior diagnosis of tuberculosis or other opportunistic infections.
    Dronda F; Sobrino P; Hernández-Novoa B; Caro-Murillo AM; Montero M; Iribarren JA; Sanz J; Del Mar Alonso M; Labarga P; Bernal E; Moreno S;
    Curr HIV Res; 2011 Jun; 9(4):229-36. PubMed ID: 21631429
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Patients presenting with AIDS in the HAART era: a collaborative cohort analysis.
    Mussini C; Manzardo C; Johnson M; Monforte Ad; Uberti-Foppa C; Antinori A; Gill MJ; Sighinolfi L; Borghi V; Lazzarin A; Miró JM; Sabin C;
    AIDS; 2008 Nov; 22(18):2461-9. PubMed ID: 19005269
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical outcome of HIV-infected patients with sustained virologic response to antiretroviral therapy: long-term follow-up of a multicenter cohort.
    Gutierrez F; Padilla S; Masiá M; Iribarren JA; Moreno S; Viciana P; Muñoz L; Gómez Sirvent JL; Vidal F; López-Aldeguer J; Blanco JR; Leal M; Rodríguez-Arenas MA; Perez Hoyos S;
    PLoS One; 2006 Dec; 1(1):e89. PubMed ID: 17183720
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunological and virological responses to highly active antiretroviral therapy in a non-clinical trial setting in a developing Caribbean country.
    Kilaru KR; Kumar A; Sippy N; Carter AO; Roach TC
    HIV Med; 2006 Mar; 7(2):99-104. PubMed ID: 16420254
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Simultaneous HAART improves survival in children coinfected with HIV and TB.
    Pensi T; Hemal A; Banerjee T
    Trop Med Int Health; 2012 Jan; 17(1):52-8. PubMed ID: 21967134
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of hepatitis C virus (HCV) viremia and HCV genotype in the immune recovery from highly active antiretroviral therapy in a cohort of antiretroviral-naive HIV-infected individuals.
    Antonucci G; Girardi E; Cozzi-Lepri A; Capobianchi MR; De Luca A; Puoti M; Petrelli E; Carnevale G; Rizzardini G; Grossi PA; Viganò P; Moioli MC; Carletti F; Solmone M; Ippolito G; Monforte AD; ;
    Clin Infect Dis; 2005 Jun; 40(12):e101-9. PubMed ID: 15909251
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Initiating highly active antiretroviral therapy and continuity of HIV care: the impact of incarceration and prison release on adherence and HIV treatment outcomes.
    Palepu A; Tyndall MW; Chan K; Wood E; Montaner JS; Hogg RS
    Antivir Ther; 2004 Oct; 9(5):713-9. PubMed ID: 15535408
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of hepatitis C infection on progression of HIV disease and early response to initial antiretroviral therapy.
    Sullivan PS; Hanson DL; Teshale EH; Wotring LL; Brooks JT
    AIDS; 2006 May; 20(8):1171-9. PubMed ID: 16691069
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Incidence of tuberculosis in HIV-infected patients receiving HAART: interaction between TST and CD4 count.
    Martín-Echevarria E; Rodríguez-Zapata M; Torralba M; Fernández JM; Moreno A; Casado JL; Dronda F; Pérez-Elías MJ; Navas E; Moreno S
    Int J Tuberc Lung Dis; 2011 Oct; 15(10):1347-52. PubMed ID: 22283893
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Survival of HIV-infected patients after starting tuberculosis treatment: a prospective cohort study.
    Maruza M; Albuquerque MF; Braga MC; Barbosa MT; Byington R; Coimbra I; Moura LV; Batista JD; Diniz GT; Miranda-Filho DB; Lacerda HR; Rodrigues LC; Ximenes RA
    Int J Tuberc Lung Dis; 2012 May; 16(5):618-24. PubMed ID: 22410415
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Incidence of tuberculosis and early mortality in a large cohort of HIV infected patients receiving antiretroviral therapy in a tertiary hospital in Addis Ababa, Ethiopia.
    Kassa A; Teka A; Shewaamare A; Jerene D
    Trans R Soc Trop Med Hyg; 2012 Jun; 106(6):363-70. PubMed ID: 22521216
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Virological control during the first 6-18 months after initiating highly active antiretroviral therapy as a predictor for outcome in HIV-infected patients: a Danish, population-based, 6-year follow-up study.
    Lohse N; Kronborg G; Gerstoft J; Larsen CS; Pedersen G; Pedersen C; Sørensen HT; Obel N
    Clin Infect Dis; 2006 Jan; 42(1):136-44. PubMed ID: 16323104
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mortality and causes of death in adults receiving highly active antiretroviral therapy in Senegal: a 7-year cohort study.
    Etard JF; Ndiaye I; Thierry-Mieg M; Guèye NF; Guèye PM; Lanièce I; Dieng AB; Diouf A; Laurent C; Mboup S; Sow PS; Delaporte E
    AIDS; 2006 May; 20(8):1181-9. PubMed ID: 16691070
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Determinants of clinical progression in antiretroviral-naive HIV-infected patients starting highly active antiretroviral therapy. Aquitaine Cohort, France, 1996-2002.
    Bonnet F; Thiébaut R; Chêne G; Neau D; Pellegrin JL; Mercié P; Beylot J; Dabis F; Salamon R; Morlat P;
    HIV Med; 2005 May; 6(3):198-205. PubMed ID: 15876287
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characteristics of HIV-infected tuberculosis patients in Thailand.
    Mankatittham W; Likanonsakul S; Thawornwan U; Kongsanan P; Kittikraisak W; Burapat C; Akksilp S; Sattayawuthipong W; Srinak C; Nateniyom S; Tasaneeyapan T; Varma JK
    Southeast Asian J Trop Med Public Health; 2009 Jan; 40(1):93-103. PubMed ID: 19323040
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical experience of the 23-valent capsular polysaccharide pneumococcal vaccination in HIV-1-infected patients receiving highly active antiretroviral therapy: a prospective observational study.
    Hung CC; Chen MY; Hsieh SM; Hsiao CF; Sheng WH; Chang SC
    Vaccine; 2004 May; 22(15-16):2006-12. PubMed ID: 15121313
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Outpatient pharmacy care and HIV viral load response among patients on HAART.
    Castillo E; Palepu A; Beardsell A; Akagi L; Yip B; Montaner JS; Hogg RS
    AIDS Care; 2004 May; 16(4):446-57. PubMed ID: 15203413
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictive factors for immunological and virological endpoints in Thai patients receiving combination antiretroviral treatment.
    Srasuebkul P; Ungsedhapand C; Ruxrungtham K; Boyd MA; Phanuphak P; Cooper DA; Law MG
    HIV Med; 2007 Jan; 8(1):46-54. PubMed ID: 17305932
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of hepatitis B virus co-infection on response to highly active antiretroviral treatment and outcome in HIV-infected individuals: a nationwide cohort study.
    Omland LH; Weis N; Skinhøj P; Laursen A; Christensen PB; Nielsen HI; Møller A; Engsig F; Sørensen HT; Obel N
    HIV Med; 2008 May; 9(5):300-6. PubMed ID: 18400077
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Incidence and prognosis of CMV disease in HIV-infected patients before and after introduction of combination antiretroviral therapy.
    Salzberger B; Hartmann P; Hanses F; Uyanik B; Cornely OA; Wöhrmann A; Fätkenheuer G
    Infection; 2005 Oct; 33(5-6):345-9. PubMed ID: 16258865
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.